NGM tabled its NASH pro­gram in 2021 af­ter a key tri­al fail­ure. Now it’s re­port­ing suc­cess in a sec­ond study

Bay Area biotech NGM Bio­phar­ma­ceu­ti­cals re­port­ed Thurs­day af­ter­noon that its drug can­di­date for non-al­co­holic steato­hep­ati­tis, or NASH, im­proved re­sults on a liv­er bio­mark­er blood test in pa­tients with the most se­vere form of the dis­ease.

But the re­sults come af­ter NGM Bio de­cid­ed in 2021 against run­ning a piv­otal tri­al for the drug af­ter it failed a mid-stage tri­al in NASH pa­tients with less ad­vanced forms of the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER